Choriogonadotropin alfa

Thông tin thuốc gốc
Chỉ định và Liều dùng
Controlled ovarian hyperstimulation for assisted reproduction in infertility, Female infertility of anovulatory origin
Adult: 250 mcg as a single dose 1 day after the last dose of follicle stimulating agent. Administer only after sufficient follicular development has been determined (as indicated by serum estradiol and vaginal ultrasonography).
Chống chỉ định
Primary ovarian failure; hypothalamus or pituitary gland tumours; ovarian cyst or enlargement unrelated to polycystic ovarian syndrome (PCOS), gynaecological haemorrhages of unknown origin; mammary, ovarian, or uterine carcinoma or sex hormone dependent tumours of the reproductive tract and accessory organs; ectopic pregnancy in the past 3 months, active thromboembolic disorders, fibroid tumours of the uterus or malformation of sexual organs incompatible with pregnancy, uncontrolled thyroid or adrenal dysfunction. Postmenopausal women. Pregnancy.
Thận trọng
Patient with PCOS; history of tubal disease; recent thromboembolic disease or risk factors for thromboembolic events (e.g. personal or family history). Not indicated for other conditions such as corpus luteum insufficiency or male conditions. In women being treated for anovulatory infertility, it is recommended to have coitus on the day of and the day after receiving choriogonadotropin alfa inj. Lactation.
Tác dụng không mong muốn
Significant: Ovarian hyperstimulation syndrome (OHSS), ovarian enlargement; thromboembolic events; multiple births, pregnancy loss by miscarriage or abortion, ectopic pregnancy, premature labour, postpartum fever, congenital malformations, neoplasms of the ovary and other reproductive system (benign and malignant).
Gastrointestinal disorders: Nausea, vomiting, abdominal pain, distension, or discomfort, diarrhoea.
General disorders and administration site conditions: Inj site reactions.
Nervous system disorders: Headache.
Chỉ số theo dõi
Perform thorough gynaecologic and endocrinologic evaluations, and evaluate for hypothyroidism, adrenocortical deficiency, hyperprolactinaemia, pituitary or hypothalamic tumours before therapy. Assess the fertility potential of the male sexual partner (e.g. semen analysis) during initial evaluation. Confirm pregnancy status before initiating therapy. Obtain ultrasound and/or estradiol levels to evaluate follicle development. Assess ovulation (e.g. basal body temperature, menstruation, serum progestin level). Monitor for signs and symptoms of OHSS (e.g. gastrointestinal symptoms, severe ovarian enlargement, weight gain, dyspnoea, oliguria).
Ảnh hưởng đến kết quả xét nghiệm
May interfere with the immunological determination of serum or urinary hCG which may lead to false positive pregnancy test; interference may last for up to 10 days. May cross-react in the radioimmunoassay of LH and other gonadotrophins.
Tác dụng
Mechanism of Action: Choriogonadotropin alfa is a recombinant form of chorionic gonadotrophin that binds to LH/hCG receptor of the ovarian granulosa and theca cells in the absence of an endogenous LH surge. It stimulates late follicular maturation of the ovarian follicle and resumption of oocyte meiosis, and initiates the rupture of the pre-ovulatory ovarian follicle.
Absorption: Bioavailability: Approx 40%. Time to peak plasma concentration: 12-24 hours.
Distribution: Volume of distribution: 21.4 L.
Excretion: Via urine (10%). Terminal elimination half-life: Approx 30 hours.
Bảo quản
Pre-filled pen/syringe: Store between 2-8°C. Do not freeze. Pre-filled syringe may also be stored at ≤25°C for up to 30 days. Protect from light.
Phân loại MIMS
Hormon dinh dưỡng & các thuốc tổng hợp có liên quan
Phân loại ATC
G03GA08 - choriogonadotropin alfa ; Belongs to the class of gonadotropins. Used as ovulation stimulants.
Tài liệu tham khảo
Anon. Choriogonadotropin Alfa. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. Accessed 02/11/2021.

Anon. Chorionic Gonadotrophin [Chorionic Gonadotropin] (Recombinant). Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 02/11/2021.

Buckingham R (ed). Chorionic Gonadotrophin. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 02/11/2021.

Joint Formulary Committee. Choriogonadotropin Alfa. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. Accessed 02/11/2021.

Ovidrel 250 mcg/0.5 mL Solution for Injection in Pre-Filled Syringe or Pre-Filled Pen (Merck Sdn. Bhd.). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. Accessed 02/11/2021.

Ovidrel Injection, Solution (EMD Serono, Inc.). DailyMed. Source: U.S. National Library of Medicine. Accessed 02/11/2021.

Ovitrelle 250 mcg Solution for Injection in Pre-Filled Pen (Merck Serono Ltd). MHRA. Accessed 02/11/2021.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Choriogonadotropin alfa từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2024 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi
  • Ovitrelle
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in